Pay vs Performance Disclosure, Table


	Summary Compensation Table Total for Mr. Cordani ($)	Compensation Actually Paid to Mr. Cordani(1) ($)	Average Summary Compensation Table Total for NEOs (other than Mr. Cordani)(2) ($)	Average Compensation Actually Paid to NEOs (other than Mr. Cordani)(1)(2) ($)	Value of Initial Fixed $100 Investment Based On:		Net Income(4) (in millions) ($)	Company-Selected Measure: Adjusted Income from Operations, per Share(5) ($)
Fiscal Year					Company TSR ($)	Peer Group TSR(3) ($)
	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)

2025	22,866,134	14,585,303	6,860,004	2,751,809	144.513	148.362	5,957	29.84
2024	23,251,096	18,908,473	8,072,936	6,681,678	142.071	129.464	3,434	27.33
2023	21,047,255	8,072,673	6,801,329	3,510,666	151.573	126.210	5,164	25.09
2022	20,965,504	57,388,994	6,346,552	15,496,862	164.705	123.666	6,704	23.36
2021	19,872,266	15,448,906	7,164,215	5,229,367	112.290	126.131	5,370	20.48

Company Selected Measure Name

adjusted income from operations, per share

Named Executive Officers, Footnote

The NEOs represented in columns (d) and (e) for each year reported are as follows:

2025: Ann M. Dennison, Brian C. Evanko, Nicole S. Jones. Everett Neville, Eric P. Palmer, and Noelle K. Eder

2024: Brian C. Evanko, Noelle K. Eder, Nicole S. Jones, and Eric P. Palmer

2023: Brian C. Evanko, Noelle K. Eder, Nicole S. Jones, and Eric P. Palmer

2022: Brian C. Evanko, Noelle K. Eder, Nicole S. Jones, and Eric P. Palmer

2021: Brian C. Evanko, Nicole S. Jones, Eric P. Palmer. Timothy Wentworth, and Matthew Manders

Peer Group Issuers, Footnote

Peer Group reflects published data for the S&P 500 Health Care Index.

PEO Total Compensation Amount

$ 22,866,134

$ 23,251,096

$ 21,047,255

$ 20,965,504

$ 19,872,266

PEO Actually Paid Compensation Amount

$ 14,585,303

18,908,473

8,072,673

57,388,994

15,448,906

Adjustment To PEO Compensation, Footnote

In accordance with SEC rules, certain amounts are deducted from, or added to, the Total column of the Summary Compensation Table to determine Compensation Actually Paid for 2025.


	Summary Compensation Table Total ($)	Stock Award Deductions from Summary Compensation Table Total(i) ($)	Change in Pension Present Value Deduction from Summary Compensation Table Total(ii) ($)	Stock Award Additions to Summary Compensation Table Total(iii) ($)	Compensation Actually Paid ($)

David M. Cordani	22,866,134	(17,329,180)	(97,562)	9,145,911	14,585,303
Average Non-PEO NEOs	6,860,004	(4,380,162)	0	271,967	2,751,809

(i)Represents the grant date fair value of equity-based awards granted in 2025.

(ii)Represents the change in the actuarial present value of the accumulated benefits under defined benefit and pension plans reported in the Summary Compensation Table. The Cigna Pension Plan, Cigna Supplemental Pension Plan, and Cigna Supplemental Pension Plan of 2005 are frozen, and there were no additional service costs or any impact on prior-year benefits related to the pension plans during 2024.

(iii)Reflects the value of equity calculated in accordance with the SEC methodology for determining Compensation Actually Paid, as follows:

Mr. Cordani’s Compensation Actually Paid Equity Valuation for 2025


Award Type	Fair Value of Awards Granted in Current Year Outstanding and Unvested as of 12/31/2025 ($)	Change in Fair Value of Outstanding and Unvested Prior Year Awards as of 12/31/2025 ($)	Change in Fair Value of Awards that Vested in 2025 ($)	Fair Value of Awards Forfeited or Cancelled in 2025 ($)	Equity Value in Compensation Actually Paid ($)
	(a)	(b)	(c)	(d)	(e) = (a) + (b) + (c) - (d)

Stock Options	2,323,905	(252,499)	969,366	0	3,040,772
Restricted Stock	3,059,732	(9,317)	332,537	0	3,382,952
Strategic Perf Shares	6,441,297	(5,188,378)	1,469,268	0	2,722,187
Total	11,824,934	(5,450,194)	2,771,171	0	9,145,911

Average non-PEO NEOs Compensation Actually Paid Equity Valuation for 2025


Award Type	Fair Value of Awards Granted in Current Year Outstanding and Unvested as of 12/31/2025 ($)	Change in Fair Value of Outstanding and Unvested Prior Year Awards as of 12/31/2025 ($)	Change in Fair Value of Awards that Vested in 2025 ($)	Fair Value of Awards Forfeited or Cancelled in 2025 ($)	Equity Value in Compensation Actually Paid ($)
	(a)	(b)	(c)	(d)	(e) = (a) + (b) + (c) - (d)

Stock Options	479,898	(56,768)	265,541	146,125	542,546
Restricted Stock	631,836	(2,090)	92,350	204,021	518,075
Strategic Perf Shares	770,992	(672,638)	255,978	1,142,986	(788,654)
Total	1,882,726	(731,496)	613,869	1,493,132	271,967

Non-PEO NEO Average Total Compensation Amount

$ 6,860,004

8,072,936

6,801,329

6,346,552

7,164,215

Non-PEO NEO Average Compensation Actually Paid Amount

$ 2,751,809

6,681,678

3,510,666

15,496,862

5,229,367

Adjustment to Non-PEO NEO Compensation Footnote

In accordance with SEC rules, certain amounts are deducted from, or added to, the Total column of the Summary Compensation Table to determine Compensation Actually Paid for 2025.


	Summary Compensation Table Total ($)	Stock Award Deductions from Summary Compensation Table Total(i) ($)	Change in Pension Present Value Deduction from Summary Compensation Table Total(ii) ($)	Stock Award Additions to Summary Compensation Table Total(iii) ($)	Compensation Actually Paid ($)

David M. Cordani	22,866,134	(17,329,180)	(97,562)	9,145,911	14,585,303
Average Non-PEO NEOs	6,860,004	(4,380,162)	0	271,967	2,751,809

(i)Represents the grant date fair value of equity-based awards granted in 2025.

(iii)Reflects the value of equity calculated in accordance with the SEC methodology for determining Compensation Actually Paid, as follows:

Mr. Cordani’s Compensation Actually Paid Equity Valuation for 2025


Award Type	Fair Value of Awards Granted in Current Year Outstanding and Unvested as of 12/31/2025 ($)	Change in Fair Value of Outstanding and Unvested Prior Year Awards as of 12/31/2025 ($)	Change in Fair Value of Awards that Vested in 2025 ($)	Fair Value of Awards Forfeited or Cancelled in 2025 ($)	Equity Value in Compensation Actually Paid ($)
	(a)	(b)	(c)	(d)	(e) = (a) + (b) + (c) - (d)

Stock Options	2,323,905	(252,499)	969,366	0	3,040,772
Restricted Stock	3,059,732	(9,317)	332,537	0	3,382,952
Strategic Perf Shares	6,441,297	(5,188,378)	1,469,268	0	2,722,187
Total	11,824,934	(5,450,194)	2,771,171	0	9,145,911

Average non-PEO NEOs Compensation Actually Paid Equity Valuation for 2025


Award Type	Fair Value of Awards Granted in Current Year Outstanding and Unvested as of 12/31/2025 ($)	Change in Fair Value of Outstanding and Unvested Prior Year Awards as of 12/31/2025 ($)	Change in Fair Value of Awards that Vested in 2025 ($)	Fair Value of Awards Forfeited or Cancelled in 2025 ($)	Equity Value in Compensation Actually Paid ($)
	(a)	(b)	(c)	(d)	(e) = (a) + (b) + (c) - (d)

Stock Options	479,898	(56,768)	265,541	146,125	542,546
Restricted Stock	631,836	(2,090)	92,350	204,021	518,075
Strategic Perf Shares	770,992	(672,638)	255,978	1,142,986	(788,654)
Total	1,882,726	(731,496)	613,869	1,493,132	271,967

Compensation Actually Paid vs. Total Shareholder Return

Compensation Actually Paid Versus Company TSR and Peer Group TSR

Over the five-year period (2021–2025), the Company’s cumulative TSR grew by 44.5%. Over the same period, cumulative TSR for the S&P 500 Health Care Index grew by 48.4%. Over this same period, Compensation Actually Paid for the PEO and the average of other NEOs decreased by 5.6% and 48.3%, respectively. Over the five-year period, Mr. Cordani’s and the other NEOs’ Compensation Actually Paid amounts were generally aligned with the Company’s TSR as compared to the S&P 500 Health Care Index TSR. This is due primarily to the Company’s use of equity incentives, which are tied directly to the Company’s stock price and financial performance on an absolute basis and relative to its peers. In addition, 50% of an SPS award’s payout is aligned to relative TSR performance as compared to a custom peer group as described in the CD&A within the section titled “Executive Compensation Policies and Practices.” The average Compensation Actually Paid for the non-PEO NEOs was also impacted by forfeitures of equity awards by NEOs that did not serve as executive officers on December 31, 2025.

The graph below compares The Cigna Group cumulative TSR to the S&P 500 Index and the S&P 500 Health Care Index for the five-year period ended December 31, 2025, which we believe provides a more complete understanding of the Company’s market performance given the longer time horizon. The stock performance shown in the graph is not intended to forecast or be indicative of future performance.

*Assumes that the value of the investment in The Cigna Group common stock and each index was $100 on December 31, 2020 and that all dividends were reinvested.

Compensation Actually Paid vs. Net Income

Compensation Actually Paid Versus Net Income

Over the five-year period (2021–2025), the Company’s net income increased by approximately 11%. Over this same period, Compensation Actually Paid for the PEO and the average of other NEOs decreased by 5.6% and 48.3%, respectively. This is due to the following:

•the significant emphasis the Company places on equity incentives, which are more sensitive to absolute stock price performance and stock price performance relative to peers;

•the forfeiture of certain equity awards during 2025 by non-PEO NEOs who did not serve as executive officers on December 31, 2025; and

•the fact that the Company does not use year-over-year changes in net income to determine compensation levels or incentive plan payouts. Instead, adjusted income from operations and adjusted income from operations, per share have been the Company’s income measures of performance in its incentive plans and the Company’s most important performance measures for determining compensation.

Compensation Actually Paid vs. Company Selected Measure

Compensation Actually Paid Versus Adjusted Income from Operations per Share

Over the five-year period (2021–2025), the Company’s adjusted income from operations, per share grew by 45.7%. Over this same period, Compensation Actually Paid for the PEO and the average of other NEOs decreased by 5.6% and 48.3%, respectively. Similar to the discussion of the relationship between Compensation Actually Paid and Company/Peer Group TSR above, Mr. Cordani and other NEOs’ Compensation Actually Paid amounts were generally aligned with the Company’s adjusted income from operations, per share results over the five-year reporting period. Long-term goals tied to adjusted income from operations, per share account for 50% of each SPS award’s total payout. Final results for adjusted income from operations, per share in years 2021, 2022, 2023, and 2024 relative to internal goals established at the beginning of each SPS award’s performance measurement period contributed to the Compensation Actually Paid values for Mr. Cordani and other NEOs seen in 2025. The average Compensation Actually Paid for the non-PEO NEOs was also impacted by forfeitures of equity awards by NEOs that did not serve as executive officers on December 31, 2025.

Total Shareholder Return Vs Peer Group

Compensation Actually Paid Versus Company TSR and Peer Group TSR

*Assumes that the value of the investment in The Cigna Group common stock and each index was $100 on December 31, 2020 and that all dividends were reinvested.

Total Shareholder Return Amount

$ 144.513

142.071

151.573

164.705

112.29

Peer Group Total Shareholder Return Amount

148.362

129.464

126.21

123.666

126.131

Net Income (Loss)

$ 5,957,000,000

$ 3,434,000,000

$ 5,164,000,000

$ 6,704,000,000

$ 5,370,000,000

Company Selected Measure Amount | uS_Dollar_Per_Share

29.84

27.33

25.09

23.36

20.48

PEO Name

David M. Cordani

Additional 402(v) Disclosure

Reflects “Shareholders’ Net Income” per SEC requirements.

Measure:: 1

Adjusted Income from Operations

Measure:: 2

Adjusted Revenues

Measure:: 3

Growth in Specialty Pharmacy Prescriptions

Measure:: 4

Relative Total Shareholder Return

Measure:: 5

Non-GAAP Measure Description

Adjusted Income from Operations, per Share

For purposes of this section, we have identified adjusted income from operations, per share as our Company-Selected Measure, the calculation of which is described in our Annual Report on Form 10-K for the year ended December 31, 2025. Additional information regarding our use of non-GAAP measures and reconciliations to the most directly comparable GAAP measure can be found on Annex A.

Measure:: 6

Customer & Patient Satisfaction

Measure:: 7

PEO | Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table

Employee Engagement

PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

$ (97,562)

PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table

(17,329,180)

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

9,145,911

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

11,824,934

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

(5,450,194)

PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year

2,771,171

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested, Stock Options [Member]

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested, Stock Options [Member]

2,323,905

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year, Stock Options [Member]

(252,499)

PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year, Stock Options [Member]

969,366

PEO | Equity Awards Adjustments, Excluding Value Reported in the Compensation Table, Stock Options [Member]

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested, Restricted Stock [Member]

3,040,772

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested, Restricted Stock [Member]

3,059,732

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year, Restricted Stock [Member]

(9,317)

PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year, Restricted Stock [Member]

332,537

PEO | Equity Awards Adjustments, Excluding Value Reported in the Compensation Table, Restricted Stock [Member]

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested, Strategic Perf Shares [Member]

3,382,952

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested, Strategic Perf Shares [Member]

6,441,297

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year, Strategic Perf Shares [Member]

(5,188,378)

PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year, Strategic Perf Shares [Member]

1,469,268

PEO | Equity Awards Adjustments, Excluding Value Reported in the Compensation Table, Strategic Perf Shares [Member]

Non-PEO NEO | Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table

2,722,187

Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table

(4,380,162)

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

271,967

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

1,882,726

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

(731,496)

Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year

613,869

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested, Stock Options [Member]

1,493,132

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested, Stock Options [Member]

479,898

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year, Stock Options [Member]

(56,768)

Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year, Stock Options [Member]

265,541

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in the Compensation Table, Stock Options [Member]

146,125

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested, Restricted Stock [Member]

542,546

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested, Restricted Stock [Member]

631,836

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year, Restricted Stock [Member]

(2,090)

Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year, Restricted Stock [Member]

92,350

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in the Compensation Table, Restricted Stock [Member]

204,021

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested, Strategic Perf Shares [Member]

518,075

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested, Strategic Perf Shares [Member]

770,992

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year, Strategic Perf Shares [Member]

(672,638)

Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year, Strategic Perf Shares [Member]

255,978

Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in the Compensation Table, Strategic Perf Shares [Member]

1,142,986

Award Timing Disclosures [Line Items]

$ (788,654)

Award Timing Disclosure

12 Months Ended

Dec. 31, 2025

USD ($)

$ / shares

Award Timing MNPI Disclosure

Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Non-Public Information

In March 2024, we adopted an Equity Grant Policy whereby all grants of Company securities to employees and consultants under our equity compensation plans, including option awards, shall be made on the next succeeding “Grant Date” after the date the Company has determined to issue the grant. Each of March 1, June 1, September 1, and December 1 are “Grant Dates” under the Equity Grant Policy, and if the Grant Date is not a business day, then the award shall be made on the business day immediately preceding the applicable Grant Date. While the policy provides that grants of options, stock appreciation rights, and similar instruments with option-like features shall not be timed in connection with the release of material non-public information, any grant of such awards made pursuant to the aforementioned “Grant Date” policy will not be deemed to violate the policy. Finally, the Equity Grant Policy permits our Board and/or the Committee the sole discretion to grant Company securities at a time other than as set forth above in extraordinary circumstances.

Option Award Disclosure

The following table contains information required by Item 402(x)(2) of Regulation S-K regarding stock options granted to our NEOs in fiscal year 2025 during the period from four business days before to one business day after the filing of the Company’s periodic reports on Forms 10-K and 10-Q or current reports on Forms 8-K that contained material nonpublic information with the SEC under the Exchange Act. These awards were granted at a routine meeting of the Committee in accordance with our Equity Grant Policy.


Name	Grant date	Number of securities underlying the award	Exercise price of the award ($/Sh)	Grant date fair value of the award	Percentage change in the closing market price of the securities underlying the award between the trading day immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information

David M. Cordani	2/28/2025	39,476	$305.855	$3,400,019	(0.62)	%
Ann M. Dennison	2/28/2025	5,806	$305.855	$500,064	(0.62)	%
Brian C. Evanko	2/28/2025	19,158	$305.855	$1,650,055	(0.62)	%
Nicole S. Jones	2/28/2025	11,176	$305.855	$962,575	(0.62)	%
Everett Neville	2/28/2025	6,386	$305.855	$550,018	(0.62)	%
Eric P. Palmer	2/28/2025	19,158	$305.855	$1,650,055	(0.62)	%
Noelle K. Eder	2/28/2025	11,176	$305.855	$962,575	(0.62)	%

Award Timing Method

Award Timing Predetermined

true

Award Timing MNPI Considered

true

Award Timing, How MNPI Considered

While the policy provides that grants of options, stock appreciation rights, and similar instruments with option-like features shall not be timed in connection with the release of material non-public information, any grant of such awards made pursuant to the aforementioned “Grant Date” policy will not be deemed to violate the policy. Finally, the Equity Grant Policy permits our Board and/or the Committee the sole discretion to grant Company securities at a time other than as set forth above in extraordinary circumstances.

MNPI Disclosure Timed for Compensation Value

false

Awards Close in Time to MNPI Disclosures, Table


Name	Grant date	Number of securities underlying the award	Exercise price of the award ($/Sh)	Grant date fair value of the award	Percentage change in the closing market price of the securities underlying the award between the trading day immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information

David M. Cordani	2/28/2025	39,476	$305.855	$3,400,019	(0.62)	%
Ann M. Dennison	2/28/2025	5,806	$305.855	$500,064	(0.62)	%
Brian C. Evanko	2/28/2025	19,158	$305.855	$1,650,055	(0.62)	%
Nicole S. Jones	2/28/2025	11,176	$305.855	$962,575	(0.62)	%
Everett Neville	2/28/2025	6,386	$305.855	$550,018	(0.62)	%
Eric P. Palmer	2/28/2025	19,158	$305.855	$1,650,055	(0.62)	%
Noelle K. Eder	2/28/2025	11,176	$305.855	$962,575	(0.62)	%

David M. Cordani [Member]

David M. Cordani

39,476

$ 305.855

$ 3,400,019

(0.0062)

Ann M. Dennison [Member]

Ann M. Dennison

5,806

$ 305.855

$ 500,064

(0.0062)

Brian C. Evanko [Member]

Brian C. Evanko

19,158

$ 305.855

$ 1,650,055

(0.0062)

Nicole S. Jones [Member]

Nicole S. Jones

11,176

$ 305.855

$ 962,575

(0.0062)

Everett Neville [Member]

Everett Neville

6,386

$ 305.855

$ 550,018

(0.0062)

Eric P. Palmer [Member]

Eric P. Palmer

19,158

$ 305.855

$ 1,650,055

(0.0062)

Noelle K. Eder [Member]

Noelle K. Eder

11,176

$ 305.855

$ 962,575